000			02096nam a2200457 i 4500
001			ocn972094491
003			OCoLC
005			20170314095117.0
006			m o d f
007			cr bn||||a||||
008			170210s2017 dcu ob f000 0 eng c
040			_aGPO _beng _erda _epn _cGPO _dMvI
042			_apcc
043			_an-us---
050	1	4	_aKF27 _b.J874 2016f
074			_a1020-C (online)
086	0		_aY 4.J 89/1:114-97
088			_aSerial no. 114-97 (United States. Congress. House. Committee on the Judiciary)
099			_aY 4.J 89/1:114-97
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on the Judiciary. _bSubcommittee on Regulatory Reform, Commercial and Antitrust Law, _eauthor.
245	1	0	_aTreating the opioid epidemic : _bthe state of competition in the markets for addiction medication : hearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fourteenth Congress, second session, September 22, 2016.
246	3	0	_aState of competition in the markets for addiction medication
264		1	_aWashington : _bU.S. Government Publishing Office, _c2017.
300			_a1 online resource (iv, 102 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
500			_aPaper version available for sale by the Superintendent of Documents, United States Government Publishing Office.
504			_aIncludes bibliographical references.
500			_a"Serial no. 114-97."
500			_aCRDP Program record.
588			_aDescription based on online resource; title from PDF title screens (FDsys, viewed on Feb. 10, 2017).
650		0	_aOpioid abuse _xTreatment.
650		0	_aBuprenorphine.
650		0	_aNaloxone.
650		0	_aPrescription pricing _zUnited States.
650		0	_aDrugs _xPrices _zUnited States.
650		0	_aPharmaceutical industry _zUnited States.
650		0	_aCompetition _zUnited States.
655		7	_aLegislative hearings. _2lcgft
856	4	0	_uhttp://purl.fdlp.gov/GPO/gpo77020
999			_c258174 _d258174